Kamu erişimi zorunlu olan makaleler - Rajarshi GuhaDaha fazla bilgi edinin
Hiçbir yerde sunulmuyor: 1
Utilizing high throughput screening data for predictive toxicology models: protocols and application to MLSCN assays
R Guha, SC Schürer
Journal of computer-aided molecular design 22, 367-384, 2008
Zorunlu olanlar: US National Institutes of Health
Bir yerde sunuluyor: 65
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
Y Yang, AL Shaffer, NCT Emre, M Ceribelli, M Zhang, G Wright, W Xiao, ...
Cancer cell 21 (6), 723-737, 2012
Zorunlu olanlar: US National Institutes of Health
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
LA Mathews Griner, R Guha, P Shinn, RM Young, JM Keller, D Liu, ...
Proceedings of the National Academy of Sciences 111 (6), 2349-2354, 2014
Zorunlu olanlar: US National Institutes of Health
Unexplored therapeutic opportunities in the human genome
TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ...
Nature reviews Drug discovery 17 (5), 317-332, 2018
Zorunlu olanlar: US National Institutes of Health, European Molecular Biology Laboratory …
High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy
SA Hasson, LA Kane, K Yamano, CH Huang, DA Sliter, E Buehler, ...
Nature 504 (7479), 291-295, 2013
Zorunlu olanlar: US National Institutes of Health
Open source drug discovery with the malaria box compound collection for neglected diseases and beyond
WC Van Voorhis, JH Adams, R Adelfio, V Ahyong, MH Akabas, P Alano, ...
PLoS Pathog 12 (7), e1005763, 2016
Zorunlu olanlar: US National Science Foundation, Bill & Melinda Gates Foundation, US National …
RNA polymerase II regulates topoisomerase 1 activity to favor efficient transcription
L Baranello, D Wojtowicz, K Cui, BN Devaiah, HJ Chung, KY Chan-Salis, ...
Cell 165 (2), 357-371, 2016
Zorunlu olanlar: US National Institutes of Health
PAX3–FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability
BE Gryder, ME Yohe, HC Chou, X Zhang, J Marques, M Wachtel, ...
Cancer Discovery 7 (8), 884-899, 2017
Zorunlu olanlar: US National Institutes of Health
What are we ‘tweeting’about obesity? Mapping tweets with topic modeling and Geographic Information System
D Ghosh, R Guha
Cartography and geographic information science 40 (2), 90-102, 2013
Zorunlu olanlar: US National Institutes of Health
Pharos: collating protein information to shed light on the druggable genome
DT Nguyen, S Mathias, C Bologa, S Brunak, N Fernandez, A Gaulton, ...
Nucleic acids research 45 (D1), D995-D1002, 2017
Zorunlu olanlar: US National Institutes of Health
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
M Ceribelli, PN Kelly, AL Shaffer, GW Wright, W Xiao, Y Yang, ...
Proceedings of the National Academy of Sciences 111 (31), 11365-11370, 2014
Zorunlu olanlar: US National Institutes of Health
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives
KC Bulusu, R Guha, DJ Mason, RPI Lewis, E Muratov, YK Motamedi, ...
Drug discovery today 21 (2), 225-238, 2016
Zorunlu olanlar: US National Institutes of Health, UK Engineering and Physical Sciences …
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
GW Rhyasen, L Bolanos, J Fang, A Jerez, M Wunderlich, C Rigolino, ...
Cancer cell 24 (1), 90-104, 2013
Zorunlu olanlar: US National Institutes of Health
On exploring structure–activity relationships
R Guha
In silico models for drug discovery, 81-94, 2013
Zorunlu olanlar: US National Institutes of Health
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses
R Jossé, SE Martin, R Guha, P Ormanoglu, TD Pfister, PM Reaper, ...
Cancer research 74 (23), 6968-6979, 2014
Zorunlu olanlar: US National Institutes of Health
Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository
N Singh, R Guha, MA Giulianotti, C Pinilla, RA Houghten, ...
Journal of chemical information and modeling 49 (4), 1010-1024, 2009
Zorunlu olanlar: US National Institutes of Health
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets
J Yuan, KCC Cheng, RL Johnson, R Huang, S Pattaradilokrat, A Liu, ...
Science 333 (6043), 724-729, 2011
Zorunlu olanlar: US National Institutes of Health
A druggable TCF4-and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm
M Ceribelli, ZE Hou, PN Kelly, G Wright, K Ganapathi, MO Evbuomwan, ...
Cancer cell 30 (5), 764-778, 2016
Zorunlu olanlar: US National Institutes of Health
High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations
BT Mott, RT Eastman, R Guha, KS Sherlach, A Siriwardana, P Shinn, ...
Scientific reports 5 (1), 13891, 2015
Zorunlu olanlar: US National Institutes of Health
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family
LM Pouliot, YC Chen, J Bai, R Guha, SE Martin, MM Gottesman, MD Hall
Cancer research 72 (22), 5945-5955, 2012
Zorunlu olanlar: US National Institutes of Health
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir